Drug Trial Radar · NCT07016516
A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jun 7, 2025
Primary completion
Sep 8, 2025
Study completion Sep 8, 2025
Sponsor
- Lead sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is a Phase I, single-center, randomized, double-blind, placebo-controlled study conducted in healthy Chinese adult subjects. The purpose of this study is to learn about: * Safety and tolerability of PRT-064040 nasal spray in healthy adult subjects. * Pharmacokinetics after single and multiple dose of PRT-064040 nasal spray in healthy Chinese adult subjects. This study is divided into two parts: * Eligible subjects in Part A will receive a single dose of PRT-064040 nasal spray or placebo. * Eligible subjects in Part B will receive multiple doses of PRT-064040 nasal spray or placebo, administered once daily (QD) for a total of 7 consecutive days.
Conditions
- Migraine
Interventions
PRT-064040 nasal sprayDrug
A single dose of PRT-064040 nasal spray at one of six dose levels
PlaceboDrug
A single dose of Placebo at one of six dose levels
PRT-064040 nasal sprayDrug
Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
PlaceboDrug
Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse eventsTime frame: From first dose to maximum of 2 days post last dose administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Hospital of Changsha
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.